Organic Active Ingredients TRIZ Cases

CE TOFMS detects specific metabolites to predict therapeutic response, avoiding ineffective treatments and adverse events.

Aceclidine eye drops activate M1 and M3 receptors to increase depth of focus while avoiding distance vision loss.

Conjugating disorazoles with cell-binding molecules concentrates cytotoxicity at tumor sites while reducing systemic toxicity.

A double extrusion process creates a biodegradable polymer matrix that holds dexamethasone within an ocular implant.

Crenezumab targets the C-terminal region of amyloid beta to slow disease progression without causing adverse events like ARIA.

Small molecule IDH1 inhibitors block enzyme activity to disrupt antioxidant defense mechanisms in cancer cells.

Administering intravenous melatonin before percutaneous coronary intervention reduces myocardial infarct size by scavenging free radicals during reperfusion.

Buoyant HPMC and alginate matrices retain bergenin in the stomach, preventing intestinal degradation and enhancing bioavailability by four-fold.

Enzymatically synthesized poly(amine-co-esters) form stable nano-sized polyplexes for nucleic acid delivery.

AICA riboside analogs restore myocardial ATP levels to resolve the trade-off between symptom management and mortality reduction in acute heart failure.

Vinylogous phenethylamine compounds release dopamine and inhibit serotonin uptake while minimizing activity at serotonin-2 receptors to reduce adverse effects.

Optimized adhesive layer composition balances ropinirole concentration with mechanical adhesion properties.

A quinoxaline derivative inhibits PDE9 to modulate cGMP levels and relax urethral smooth muscle.

Sinter powder blends using radiofrequency energy to bond lossy coated particles into tablets with high hardness and rapid disintegration.

Modified pyrone derivatives resist HIV propagation while reducing severe side effects and overcoming drug resistance.

Cepharanthine dihydrochloride salt recrystallizes into polymorphic mixtures to overcome low solubility of free base alkaloids in filovirus treatments.

Novel dioxino-oxazinopyrimidine compounds traverse the blood-brain barrier to inhibit PI3K and suppress tumor growth in malignant gliomas.

Pharmacological Hedgehog pathway inhibition replaces invasive surgery to manage cartilage tumors and prevent malignant progression.

Segmented multilayer coatings with hydrophobic polymer topcoats prevent calcium salt encrustation on ureteral stents through sustained inhibitor release.

Chloroquine triggers Par-4 secretion from normal cells, inducing selective cancer cell apoptosis while sparing healthy tissue.

Pyridylthiazole urea compounds overcome low potency and selectivity by targeting both ROCK1 and ROCK2 isoforms.

A double-layer tablet separates opioid agonists and antagonists to maintain analgesic efficacy while reducing side effects.

Nanoparticle delivery of TCF/LEF inhibitors targets Wnt pathway aberrant expression in cancer stem cells to overcome treatment resistance.

Segmented miRNA formulations target MDM2, A3G, and ADAR1p150 transcripts to reduce leukemia stem cell propagation.

High-concentration leucine and vitamin D3 overcome age-related muscle sensitivity loss, restoring protein synthesis rates.

Structural modifications of RAD51 inhibitors improve metabolic stability and oral exposure while reducing DNA double strand break repair.

Microcapsules encapsulate nanobubbles and drugs to enable precise therapeutic targeting via acoustic cavitation.

Antibodies detect aberrant post-translational modifications on amplified EGFR to minimize normal tissue uptake and enhance anti-tumor activity.

Gel composition replaces painful mechanical nasal packing by applying pressure and promoting coagulation, eliminating infection risks and manual removal.

Solid nicotine salts resolve oil form storage issues by using specific coformers to improve photostability and prevent toxic degradation.

Administering TNFα antagonists blocks inflammatory signaling pathways, preventing post-operative cognitive dysfunction in patients.

Steroidal cationic lipids improve pharmacokinetic properties and targeted delivery precision while reducing toxicity in diverse cell types.

Selective neu1 and neu3 inhibitors block LDL desialylation to reduce arterial inflammation without altering plasma cholesterol levels.

Pyrazolopyrazine derivatives overcome insufficient PTPN11 inhibition by optimizing molecular structure for tumor growth suppression.

Bifunctional compounds recruit Bruton's tyrosine kinase to ubiquitin ligase for targeted proteolytic degradation.

A bi-layer tablet combines immediate release promethazine with controlled release acetaminophen and hydrocodone.

Benzomorphan analogs modulate mu, delta, and kappa opioid receptors to provide analgesia while minimizing constipation and tolerance.

A buccal nicotine spray combines mucolytic agents to reduce mucus viscosity and accelerate drug permeation across the oral mucosa.

C-glycosides inhibit the TGF-β1 signaling pathway to reduce fibroblast conversion, addressing incomplete scar removal by current methods.

A high-temperature endoglucanase method produces defined DP7-DP9 xyloglucan oligosaccharides from polysaccharide sources.

Crosslinked hyaluronic acid gels extend residence time in joints to reduce injection frequency while avoiding the gastric ulcers caused by NSAIDs.

Angiotensin-(1-7) receptor agonists treat cognitive dysfunction by reducing inflammatory cytokines and reactive oxygen species in the central nervous system.

Liposomes encapsulate 2-deamino-2-pyrrolino-daunorubicin to reduce systemic toxicity while maintaining cancer cell killing efficacy.

MPC inhibitors block mitochondrial pyruvate transport to prevent fibrosis progression in primary congenital cardiomyopathies.

Parathyroid hormone combined with a DPP IV inhibitor prolongs SDF-1 upregulation, resolving inefficient stem cell homing in ischemic disorders.

Combines anti-CD79b immunoconjugates with immunomodulatory agents and anti-CD20 antibodies to treat B-cell proliferative disorders.

Spraying prebiotic liquid on a porous mushroom core isolates ergothioneine to increase concentration while reducing gastrointestinal discomfort.

A MUC-1 liposomal vaccine formulation targets cancer cells to improve patient survival rates.

Aqueous crystallization eliminates toxic organic solvents while boosting solubility and bioavailability of canagliflozin.

Acid treatment stabilizes Rosmarinic acid during extraction, increasing yield while the composition delays lung senescence.

4-methyl-pentaaza-naphthalene derivatives inhibit phosphodiesterase 2 and 10 to improve cognitive function.

Trioxacarcin analogs join antibodies to target cancer cells, reducing systemic toxicity while maintaining high cytotoxic potency.

A novel Cobicistat preparation process replaces pyrophoric bases with stable alkali metal salts to improve reaction yield and product purity.

A double-stranded nucleic acid complex delivers antisense oligonucleotides into the cell nucleus.

Antagonist compounds reverse tumor-induced immunosuppression by blocking adenosine binding, expanding treatment options beyond checkpoint inhibitors.

A Lazertinib pharmaceutical composition uses microcrystalline cellulose and mannitol diluents to enhance drug release.

A purified human milk oligosaccharide composition retains structural diversity while removing lactose and minerals through enzymatic digestion and membrane filtration.

Rigid GalNAc ligands direct RNAi agents to liver cells, reducing off-target effects through hepatocyte-specific uptake.

Auxiliary compounds in a powderous vitamin E formulation raise the minimum ignition energy, reducing dust explosion hazards while maintaining free flowability.

Genistein treats dry eye syndrome by stimulating lacrimal glands without the side effects of systemic hormone replacement therapy.

Novel enfumafungin derivatives inhibit (1,3)-β-D-glucan synthase to treat fungal infections while minimizing mammalian toxicity.

A 1,2,4-triazolo[1,5a]pyridine derivative inhibits JAK2 kinase activity to treat chronic inflammation.

Amino acid infusion restores mTOR signaling to rescue kidney endocytosis, reducing serum creatinine and blood urea nitrogen levels.

A chemical process synthesizes Ibrutinib using inorganic bases and methylsulfonyl chloride to replace complex reagent systems.

Novel PI3K inhibitor compounds target specific enzyme isoforms through precise structural design, resolving selectivity issues in cancer treatment.

Hydrophobic weak base chemotherapeutic agents accumulate in lysosomes and rupture upon illumination to achieve marked cytotoxicity.

A pyrimidine derivative compound inhibits kinase activity in cancer cells expressing mutant EGFR or amplified MET.

Two-stage oxidation breaks ether and carbon-carbon bonds to yield valuable monomers for cosmetics.

Synthesizing pure R-Carphedon enantiomers via asymmetric N-alkylation to isolate specific pharmacological properties.

Fusion proteins combine prostate antigens with carrier molecules to elicit targeted immune responses against cancer cells.

Isoxazole-pyrazole derivatives act as selective inverse agonists at the GABA A α5 receptor, reducing proconvulsant activity while enhancing cognitive function.

Strontium-based topical formulations selectively inhibit Type C nociceptors to reduce pain and inflammation without causing numbness or loss of function.

A heparin and magnesium salt combination blocks viral attachment to host cells.

Fatty acid esters mediate tocopherol glycinate interactions to prevent viscosity reduction and separation during storage.

5' triphosphate oligonucleotides bind RIG-I receptors to trigger cytokine production, avoiding non-targeted cell death from generic siRNAs.

Bipolar trans carotenoid salts increase oxygen diffusivity in biological tissues while maintaining solubility in aqueous solutions.

Indane derivatives inhibit the LasB elastase enzyme to disrupt established biofilms, restoring antibiotic susceptibility against resistant bacteria.

Benzyl alcohol co-solvent increases buprenorphine solubility in dispersed phase, enabling 35-55% drug load while maintaining sustained release profile.

Complementary RNA molecules neutralize SARS-CoV-2 particles to prevent long-term lung injury and scarring.

Selective JAK1 inhibitor reduces inflammation and cartilage degradation while minimizing off-target effects in osteoarthritis treatment.

Iron powder and Raney-Ni replace hazardous reagents, eliminating toxic by-products and severe temperature control requirements.

Ester-bonded polymer microspheres retain moisture to reduce wrinkle visibility without invasive procedures or infection risks.

Transfer hydrogenation with a transition metal catalyst produces diastereomerically enriched 6-amino morphinans while minimizing unwanted epimer formation.

Crystalline form A of valbenazine ditosylate uses a 2-MeTHF and water co-solvate in anisole to boost yield, solubility, and stability over prior forms.

An oscillating needle deposits biodegradable polymer microparticles directly into tissue for precise localized drug release.

Variable substituents on heterocyclic cores modulate signal transduction pathways to overcome limited efficacy of existing treatments.

Administering plinabulin after docetaxel reduces neutropenia rates while maintaining high anti-cancer efficacy through intermediary protection.

CTLA-4 aptamer conjugates target tumor cells to enhance antitumor immunity while reducing toxicity.

Polymer-coated drug particulates resolve the contradiction between rapid onset and sustained duration by segmenting particle sizes to control release kinetics.

Diazine-fused amidine compounds inhibit beta-secretase enzymes, blocking amyloid-beta formation to address Alzheimer's disease root causes.

Enzymatic plaque digestion reduces vascular trauma and restenosis risk compared to mechanical atherectomy.